Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

June 27, 2024

https://www.globenewswire.com/news-release/2024/06/27/2905181/33333/en/Coherus-BioSciences-Announces-Divestiture-of-YUSIMRY-adalimumab-aqvh-in-a-40-Million-Upfront-All-Cash-Transaction.html

REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Coherus, Nasdaq:CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash consideration of $40 million. The closing of the transaction occurred on June 26, 2024. Meitheal Pharmaceuticals, Inc. (Meitheal), a wholly owned subsidiary of HKF, will continue to commercialize YUSIMRY in the U.S.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.